HA is the natural ligand for the CD44 receptor, which is often highly overexpressed on tumor cells (e.g., colon, breast) and inflamed skin cells (e.g., psoriasis). This provides an active targeting mechanism for nanocarriers, concentrating the drug at the pathological site while sparing healthy tissues, thus reducing systemic toxicity.
Hyaluronic Acid based Targeted Drug Delivery Solution
Creative Biolabs specializes in offering precision hyaluronic acid (HA) delivery system development. We empower clients to overcome complex challenges like non-specific drug toxicity, poor drug solubility, and rapid clearance. Our services focus on synthesizing HA with optimized molecular weight and unmatched purity, securing targeted and sustained therapeutic efficacy for your innovative products.
Click Here to View more about our Services
Introduction to Hyaluronic Acid
HA is a naturally occurring linear polysaccharide, essential for the structure and function of the Extracellular Matrix (ECM) in the skin, joints, and eyes. Structurally, it is composed of repeating disaccharide units of D-glucuronic acid and N-acetyl-D-glucosamine. This simple chain structure grants it exceptional hygroscopicity, allowing a single gram to bind up to 1,000 times its weight in water, which is vital for tissue turgor and hydration. HA is rapidly and dynamically synthesized in the body by hyaluronan synthase (HAS) enzymes. The final polymer size, ranging from thousands to millions of Daltons (Da), is precisely controlled by these enzymes, a feature we replicate biotechnologically for therapeutic applications.
Advantages of Hyaluronic Acid-Based Delivery System
The inherent features of HA make it a superior choice for advanced drug delivery systems (DDS):
CD44 Active Targeting
MW Tunability
The Molecular Weight (MW) is the bio-signal. High MW HA provides excellent surface lubrication (ocular, joint), while specific Low MW fractions (e.g., 50 kDa) are engineered for deep epidermal penetration and controlled cellular signaling, ensuring the correct biological response is triggered.
Sustained and Controlled Release
Its viscoelasticity and capacity to form hydrogels, nanofibers, and micelles enable the creation of systems that prolong the drug's half-life and allow for pH- or enzyme-responsive drug release, ensuring continuous therapeutic activity.
Biocompatibility and Mucoadhesion
HA is naturally biocompatible and possesses mucoadhesive properties, which is crucial for extending the drug's residence time on mucosal surfaces like the ocular epithelium.
Applications of Hyaluronic Acid in Delivery Systems
Targeted Systemic Oncology
HA chemically couples to chemotherapy agents to form prodrugs, drastically improving drug solubility and mitigating severe side effects like cardiotoxicity. These carriers are often dual-responsive, engineered to release the active drug only upon encountering the tumor's unique microenvironment (low pH and high reducing potential), ensuring highly localized therapeutic activation.
Enhanced Ocular Drug Delivery
HA directly addresses the major limitations of eye drops, such as tear drainage and the corneal barrier. Its high viscosity and mucoadhesion significantly extend the drug's residence time on the eye surface. For glaucoma treatment, incorporating drugs like timolol into HA-modified nanoparticles has been shown to extend the therapeutic effect from 8 to 12 hours, greatly improving patient compliance.
Fig.1 Fabrication of HA for various routes of ocular drug delivery.1
Localized Dermatological Treatment
HA enables highly targeted topical therapy for inflammatory skin diseases. For psoriasis, HA-microneedle patches are used to physically bypass the stratum corneum (SC) barrier and deliver agents directly to the inflamed, CD44-overexpressing cells. Furthermore, HA acts as a potent humectant to restore the critical skin barrier function in conditions like atopic dermatitis (AD).
Table.1 Examples of HA-based delivery systems.
| Application Area | HA Formulation | Key Function | Target/Benefit |
|---|---|---|---|
| Oncology (Systemic) | Prodrugs (HA-Drug) | CD44 Active Targeting; Dual-Responsive Release | Reduced Systemic Toxicity; Localized Tumor Activation |
| Ocular Delivery | Nanoparticles/Ionic Complexes | Mucoadhesion; Viscosity Enhancement | Prolonged Residence Time; Improved Patient Compliance (Glaucoma) |
| Dermatology (Topical) | Microneedle Patches | Physical SC Barrier Penetration; CD44 Targeting | Localized Anti-Inflammatory Action (Psoriasis); Reduced Dose |
Related Services
To fully harness these advanced features, precision in HA MW and ultra-low endotoxin purity are mandatory. Creative Biolabs provides specialized HA-based delivery system development services that meet the most rigorous regulatory standards for injectables and ophthalmic devices. Contact us today to discuss your specific therapeutic goals and secure a competitive advantage through molecular precision.
Reference
- Kim, Martha, et al. "How to Fabricate Hyaluronic Acid for Ocular Drug Delivery." Pharmaceutics 16.12 (2024): 1604. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/pharmaceutics16121604
Our services are For Research Use Only. We do not provide services to individuals.
Online Inquiry
